[Pharmacological and clinical profile of bixalomer (Kiklin(®) capsules): a new therapeutic agent for hyperphosphatemia]

Nihon Yakurigaku Zasshi. 2013 Jun;141(6):333-7. doi: 10.1254/fpj.141.333.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Capsules
  • Chelating Agents / metabolism
  • Chelating Agents / pharmacology*
  • Chelating Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Coronary Disease / etiology
  • Humans
  • Hyperparathyroidism, Secondary / etiology
  • Hyperphosphatemia / drug therapy*
  • Hyperphosphatemia / etiology
  • Phosphoric Acids / metabolism
  • Polyamines / metabolism
  • Polyamines / pharmacology*
  • Polyamines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Renal Dialysis / adverse effects
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / metabolism
  • Risk

Substances

  • Capsules
  • Chelating Agents
  • Phosphoric Acids
  • Polyamines
  • bixalomer
  • phosphoric acid